Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Medtronic
Express Scripts
Healthtrust
Fish and Richardson
Moodys
Colorcon
AstraZeneca

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,002,776

« Back to Dashboard

Summary for Patent: 5,002,776
Title: Controlled absorption diltiazem formulations
Abstract:A controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming water insoluble synthetic polymer and optionally a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer, when said water soluble polymer is present, being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over not less than a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KCl at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 60% of the total diltiazem is released after four hours of measurement and 100% of the diltiazem is released no earlier than after 8 hours of measurement in said apparatus.
Inventor(s): Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Athlone, IE), Panoz; Donald E. (Tuckers Town, BM)
Assignee: Elan Corporation, PLC (Athlone, IE)
Application Number:07/273,192
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device; Process;

Drugs Protected by US Patent 5,002,776

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,002,776

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland3158/87Nov 20, 1987
Ireland822/88Mar 22, 1988

International Family Members for US Patent 5,002,776

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain 2194832 ➤ Try a Free Trial
Ireland 833057 ➤ Try a Free Trial
Switzerland 662507 ➤ Try a Free Trial
Germany 3485023 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Teva
Baxter
Moodys
Medtronic
AstraZeneca
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.